Physician profile
Seth Lyle Goolsbee
NPI 1174015523
$3,940.30
in general payments reported to CMS, 2019-2025
16 companies · $792 in 2025
The $792 reported for 2025 was more than what 87% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $518 · 2020: $162 · 2021: $580 · 2022: $648 · 2023: $577 · 2024: $662 · 2025: $792.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,018 · Entertainment: $13.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,017.73 |
| Entertainment | $13.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,789.46 | 2019-2025 | Precision7, Total30, Rhopressa |
| Johnson & Johnson Vision Care, INC. | $714.16 | 2019-2024 | |
| Bausch & Lomb Americas INC. | $498.81 | 2022-2025 | Infuse, Infuse Multifocal, Miebo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $285.18 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $149.93 | 2024-2025 | Xdemvy |
| Abbvie INC. | $92.45 | 2025 | |
| Oyster Point Pharma, INC. | $85.45 | 2022-2023 | Tyrvaya |
| Dompe US, INC. | $64.54 | 2024-2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $57.97 | 2019-2023 | Cequa |
| Novartis Pharmaceuticals Corporation | $48.34 | 2021 | |
| Kala Pharmaceuticals, INC. | $35.64 | 2020-2021 | |
| Coopervision INC. | $33.58 | 2022-2025 | Myday Contact Lens |
| Ani Pharmaceuticals, INC. | $26.94 | 2025 | Purified Cortrophin Gel |
| Abb Con-Cise Optical Group LLC | $25.86 | 2020 | |
| Sight Sciences, INC. | $18.07 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optos, INC. | $13.92 | 2024 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Goolsbee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.